139
Participants
Start Date
November 20, 2020
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
ABBV-RGX-314 Dose 1
AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
ABBV-RGX-314 Dose 2
AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
ABBV-RGX-314 Dose 3
AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
Topical Steroid
Topical Steroid
ABBV-RGX-314 Dose 4
AAV8 vector containing a transgene for anti-VEGF fab (Dose 4)
Aflibercept
Aflibercept
Mid Atlantic Retina, Philadelphia
Wilmer Eye Institute/Johns Hopkins University School of Medicine, Baltimore
Cumberland Valley Retina Consultants, Hagerstown
Duke University Eye Center, Durham
Southeast Retina Center, PC, Augusta
Charles Retina Institute, P.C., Germantown
University Retina and Macula Associates, PC, Oak Forest
Springfield Clinic, Springfield
Star Retina, Burleson
Retinal Consultants of Texas, The Woodlands
Austin Clinical Research, LLC, Austin
Retina Research Institute of Texas, LLC, Abilene
Retinal Research Institute, LLC, Phoenix
Barnet Dulaney Perkins Eye Center, Phoenix
Vision Research Center Eye Associates of New Mexico, Albuquerque
Sierra Eye Associates, Reno
Retina-Vitreous Associates Medical Group, Beverly Hills
California Eye Specialists Medical Group, Inc, Pasadena
Retinal Consultants San Diego, Poway
California Retina Consultants, Santa Barbara
California Retina Consultants, Bakersfield
Northern California Retina Vitreous Associates Medical Group, Inc., Mountain View
Retinal Diagnostic Center, Campbell
Ophthalmic Consultants of Boston, Boston
NJ Retina, Teaneck
Lead Sponsor
REGENXBIO Inc.
INDUSTRY
AbbVie
INDUSTRY